Literature DB >> 17688974

Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients.

Sílvia Busquets1, Chris Deans, Maite Figueras, Rodrigo Moore-Carrasco, Francisco J López-Soriano, Kenneth C H Fearon, Josep M Argilés.   

Abstract

BACKGROUND & AIMS: Previous studies of our research group have shown that apoptosis is present in skeletal muscle of tumour-bearing animals subject to cachexia. For this reason we decided to investigate the apoptosis in skeletal muscle of cancer patients. METHODS AND
RESULTS: In the present study, muscle biopsies from weight-losing patients with upper gastro-intestinal cancer showed a significant increase in muscle DNA fragmentation (three-fold), as compared with control subjects. The increase in DNA laddering was associated with an increase in poly(ADP-ribose) polymerase (PARP) cleavage (four-fold) as measured by western blotting. These two events indicate the presence of muscle apoptosis. These changes were associated with a decrease in MyoD protein content, suggesting important alterations in skeletal muscle physiology.
CONCLUSIONS: The results presented therefore confirm that apoptosis is also present in human subjects undergoing cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688974     DOI: 10.1016/j.clnu.2007.06.005

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  25 in total

Review 1.  The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting.

Authors:  James A Carson; Justin P Hardee; Brandon N VanderVeen
Journal:  Semin Cell Dev Biol       Date:  2015-12-01       Impact factor: 7.727

2.  A novel role for CD4+ T cells in the control of cachexia.

Authors:  Zhuangzhi Wang; Chunfang Zhao; Rosa Moya; Joanna D Davies
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting.

Authors:  Hawley E Kunz; Jessica M Dorschner; Taylor E Berent; Thomas Meyer; Xuewei Wang; Aminah Jatoi; Rajiv Kumar; Ian R Lanza
Journal:  J Biol Chem       Date:  2020-10-01       Impact factor: 5.157

4.  Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7.

Authors:  Wei A He; Federica Calore; Priya Londhe; Alessandro Canella; Denis C Guttridge; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

5.  Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice.

Authors:  Kristen A Baltgalvis; Franklin G Berger; Maria Marjorette O Peña; J Mark Davis; James P White; James A Carson
Journal:  J Appl Physiol (1985)       Date:  2010-07-22

Review 6.  Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle.

Authors:  Mark Romanick; Ladora V Thompson; Holly M Brown-Borg
Journal:  Biochim Biophys Acta       Date:  2013-03-20

7.  Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide.

Authors:  Steven T Russell; Michael J Tisdale
Journal:  Mol Cell Biochem       Date:  2009-04-30       Impact factor: 3.396

Review 8.  Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2013-03-19       Impact factor: 5.614

Review 9.  Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.

Authors:  Sumbul Ali; Jose M Garcia
Journal:  Gerontology       Date:  2014-04-08       Impact factor: 5.140

10.  Molecular profiles of Quadriceps muscle in myostatin-null mice reveal PI3K and apoptotic pathways as myostatin targets.

Authors:  Ilham Chelh; Bruno Meunier; Brigitte Picard; Mark James Reecy; Catherine Chevalier; Jean-François Hocquette; Isabelle Cassar-Malek
Journal:  BMC Genomics       Date:  2009-04-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.